# Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

> **NCT00184015** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Southern California** · enrollment: 50 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Bevacizumab and Bortezomib
- **DRUG:** Bevacizumab and Bortezomib

## Key facts

- **NCT ID:** NCT00184015
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-08-18
- **Primary completion:** 2016-08-21
- **Final completion:** 2018-08-21
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184015, "Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00184015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*